IARC Cancer Evaluation

ToxStrategies professionals can assist clients in preparing for the review of their substance of interest within the IARC (International Agency for Research on Cancer) Monograph Program. This program evaluates the potential of a substance to be a human carcinogen.  The IARC staff initiate the evaluation process by identifying experts to participate on the working group. The working group then reviews pertinent information and drafts a summary. At the cancer evaluation meeting, these drafts are reviewed, discussed, integrated, and finalized which includes voting on the classification of the agent. Meeting summaries are published in the Lancet within weeks of the meeting, followed by meeting monographs approximately a year later. Though not a regulatory body, final IARC classification status has stark global impact given the use of agent classifications by regulatory entities (e.g., Proposition 65).

Our staff have first-hand knowledge of the IARC process, having served as working group members, meeting observers, and providing support to clients in the preparation for these evaluations and identification of follow-up strategies following evaluations. In our experience, we have found it integral to be engaged in this process, beginning prior to the meeting announcement, allowing for ample time to potentially fill data gaps. Moreover, because working group members vary with each individual monograph meeting, actual evaluation and interpretation of data are unique to each meeting, thus highlighting the potential role of an observer to ensure key data are reviewed by the working group. Examples of area where our staff have experience supporting clients in various capacities related to the IARC evaluation process include:

  • Education of IARC process
  • Outlining the process and identification of specific client needs based on agent being evaluated
  • Early recognition of data submission needs
  • Implementation of strategies to fulfill data needs
  • Identification and nomination of experts
  • Meeting observation and/or observer preparation
  • IARC-like evaluation of cancer studies in human and animals
    • Study quality and reliability
    • Evaluation of body of evidence for causality
  • Assessment of mechanistic data via the Ten Key Characteristics of Carcinogens (Smith et al., 2015)
    • Identification and evaluation of information via the peer review literature
    • Mine, map, and critically evaluate high throughput screening (HTS) data (e.g., ToxCast/Tox21)
  • Summarize exposure data
    • Characterization of agent components/contaminants
    • Identification of possible contaminants/metabolites of agent that might contribute to evaluation
  • Evaluation of other relevant information
    • Evaluate relevant toxicokinetic information, noting key metabolites as well as their cancer and toxicity profiles if available
    • Assess information pertaining to susceptibility
    • Mode-of-action of cancer process and relevance to humans
  • Preliminary categorization of potential IARC classification to anticipate outcome
  • Collaboration and support of public relation efforts
  • Follow-up strategies based on classification of agent
It's only fair to share...
Email this to someone
Share on Facebook
0Tweet about this on Twitter
0Share on LinkedIn